Expertise in
32
conditions

Dr. James M. Orcutt

Oncology
Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 
Expertise in
32
conditions
Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, 
Charleston, SC 

Overview

James Orcutt is an Oncologist practicing medicine in Charleston, South Carolina.

Dr. Orcutt is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Paget Disease of the Breast, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 5 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in SC

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Charleston Hematology Oncology Associates PA
2085 Henry Tecklenburg Dr Fl 2, Charleston, SC 29414

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
A Phase II, Multicenter, Open Label Study of Bintrafusp Alfa (M7824) Monotherapy in Participants With HMGA2-expressing Triple Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: April 10, 2023
Intervention Type: Drug
Study Drug: Bintrafusp alfa
Study Phase: Phase 2
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry
Enrollment Status: Completed
Publish Date: September 28, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.
Journal: Breast cancer research : BCR
Published: January 24, 2020
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Complementary Cancer Care Inc.

86 Jonathan Lucas St, 
Charleston, SC 
 (5.7 miles away)
843-792-9300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Hawkins is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Hawkins is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Hawkins is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (5.7 miles away)
843-792-2300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Lindhorst is an Oncologist practicing medicine in Charleston, South Carolina. Dr. Lindhorst is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Brain Tumor, and Awake Craniotomy. Dr. Lindhorst is currently accepting new patients.

Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Expertise in
37
conditions
Dr. Robert K. Stuart
Hematology | Oncology
Referral may be required

MUSC University Hospital

171 Ashley Ave, 
Charleston, SC 
 (5.7 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Robert Stuart is a Hematologist and an Oncologist practicing medicine in Charleston, South Carolina. Dr. Stuart is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. James M. Orcutt

How do I make an appointment with Dr. James M. Orcutt?

You can book an appointment with Dr. James M. Orcutt by calling their office at 843-577-6957. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James M. Orcutt a top-rated expert for Non-Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James M. Orcutt is classified as an Distinguished expert for Non-Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James M. Orcutt specialize in?

While Dr. James M. Orcutt is a Oncology, they have specific expertise in Non-Hodgkin Lymphoma, Paget Disease of the Breast, and Chronic Lymphocytic Leukemia (CLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. James M. Orcutt participate in research or clinical trials?

Yes. Dr. James M. Orcutt has published 3 articles and abstracts on conditions like Non-Hodgkin Lymphoma. You can view a list of Dr. James M. Orcutt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James M. Orcutt accept my insurance?

Dr. James M. Orcutt accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 843-577-6957 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Orcutt's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 22 Advanced Conditions
    View All 79 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile